November 2020 EGRP Cancer Epidemiology News
EGRP Cancer Epidemiology News
- Survivorship Activities of the National Cancer Institute
- Funding Opportunities and Notices of Special Interest
- Grants Policy Notices
- Request for Information (RFI)
- Leadership Opportunity
- NIH Blog Posts
Survivorship Activities of the National Cancer Institute
As of January 2019, it is estimated that there are 16.9 million cancer survivors in the United States. This represents approximately 5.0% of the population. The number of cancer survivors is projected to increase to 21.7 million by 2029 and to 26.1 million by 2040.
In order to address the unique needs of the growing cancer survivor population, NCI and the Division of Cancer Control and Population Sciences (DCCPS) remain focused on supporting cancer survivorship research through more than 20 funding opportunity announcements and more than 100 active grants. See below for more NCI- and DCCPS-sponsored activities that promote cancer survivorship research.
Dr. Emily Tonorezos Joins NCI as Director of the Office of Cancer Survivorship
Emily S. Tonorezos, M.D., M.P.H., recently joined NCI’s Division of Cancer Control and Population Sciences (DCCPS) as Director of the Office of Cancer Survivorship (OCS). Prior to her appointment at NCI, Dr. Tonorezos served as Director of the Adult Long-Term Follow-Up Program at the Memorial Sloan Kettering Cancer Center and the Weill Cornell Medical College. Her research focuses on cardiometabolic consequences of cancer therapy, childhood and young adult cancer survivorship, diet and nutrition, and care coordination for this population. Dr. Tonorezos was also co-leader of the International Guideline Harmonization Group for the metabolic syndrome guidelines, and she led a recent international effort to develop recommendations for adult survivors of heritable retinoblastoma.
EGRP’s Clinical and Translational Epidemiology Branch
The Epidemiology and Genomics Research Program (EGRP) in DCCPS supports research in human populations to understand determinants of cancer occurrence and outcomes and to translate these findings to clinical and public health interventions. Within EGRP, the Clinical and Translational Epidemiology Branch (CTEB) stimulates, promotes, and supports cancer epidemiologic research to identify clinical, genomic, and lifestyle factors that improve outcomes for cancer survivors. Areas of particular interest to CTEB include, but are not limited to:
- Identification of factors (e.g., treatment regimens, comorbidities, genomics, lifestyle, body composition) that influence risk for short- and long-term adverse events and cancer outcomes,
- Changes in aging trajectories in cancer survivors, and
- Approaches to enhance cancer genetic counseling and testing for cancer survivors and those at risk.
Cancer Survivorship Webinars, Including a New Series
EGRP supports several webinar series that include the topic of cancer survivorship.
- The Body Composition and Cancer Outcomes Research Webinar Series had its first event on Thursday, November 12, 2020. Dr. Bette Caan, a senior research scientist and a nutritional epidemiologist at the Kaiser Permanente Northern California Division of Research, presented on sarcopenia and cancer survival (watch the archived video). The next event in the series will take place Thursday, December 17, 2020 from 3-4 p.m. ET with Dr. Mirza Faisal Beg from Simon Fraser University, “Automating Body Composition from Routinely Acquired CT Images - Towards 3D Measurements.”
- In 2019, NCI introduced Perspectives on Cancer and Aging: The Arti Hurria Memorial Webinar Series. Arti Hurria, M.D., was a pioneer in the fields of geriatrics and oncology and a grantee and collaborator in NCI’s Division of Cancer Control and Population Sciences. This webinar series strives to honor her legacy by creating a community of researchers dedicated to cancer and aging research and building a platform to broadly disseminate their work. On November 2, 2020, Garnet Anderson, Ph.D., of the Fred Hutchinson Cancer Research Center, and Elizabeth Cespedes Feliciano, Sc.D., M.Sc., of Kaiser Permanente Northern California, presented “Harnessing the Power of the WHI Life and Longevity after Cancer (WHI-LILAC) Study to Better Understand Cancer and Aging,” which is now available for viewing.
- For those with an interest in rare cancer etiology, risk, prognosis, and survivorship, recordings of past webinars in the Rare Cancer Webinar Series are also available.
Funding Opportunity Announcements Related to Cancer Survivorship Research
NCI-sponsored Funding Opportunity Announcements (FOAs) related to cancer survivorship research include but are not limited to:
- Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01 and R21), expires July 31, 2021
- Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 and R21), expires January 8, 2022
- Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01), expires February 12, 2022
- Core Infrastructure Support for Cancer Epidemiology Cohorts (U01), expires November 10, 2022
For more funding opportunities related to cancer survivorship research, visit the DCCPS funding opportunities webpage.
To learn more about cancer survivorship research resources in DCCPS, please visit the Office of Cancer Survivorship’s website. If you would like to speak with program staff specializing in various aspects of cancer survivorship research, view the list of survivorship program contacts.
Funding Opportunities and Notices of Special Interest
- Notices of Special Interest (NOSI):
- Availability of Administrative Supplements to Adapt/Repackage Visualization Methods for Enhancing Cancer Moonshot Data (NOT-CA-21-008)
- Administrative Supplement for Research and Capacity Building Efforts Related to Bioethical Issues (Admin Supp Clinical Trial Optional) (NOT-OD-21-020)
- Academy of Finland (AKA) – National Institutes of Health (NIH) Partnership Program (NOT-OD-21-021
- Notice of NIH Participation in Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (NOT-OD-21-011)
- Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01, Clinical Trial Not Allowed)
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00, Independent Basic Experimental Studies with Humans Required; K99/R00, Independent Clinical Trial Not Allowed; K99/R00, Independent Clinical Trial Required)
- Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03, Clinical Trial Not Allowed)
- Cancer Prevention and Control Clinical Trials Grant Program (R01, Clinical Trial Required)
- Stephen I. Katz Early Stage Investigator Research Project Grant (R01, Clinical Trial Not Allowed; R01, Basic Experimental Studies with Humans Required)
- Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01, Clinical Trial Optional; R21, Clinical Trial Optional)
- Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R01, Clinical Trial Not Allowed)
- Addressing Health Disparities among Immigrant Populations through Effective Interventions (R01, Clinical Trial Optional)
- Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21, Clinical Trial Not Allowed)
- Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33, Clinical Trial Not Allowed)
- Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21, Clinical Trial Not Allowed)
- Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33, Clinical Trial Not Allowed)
- Cancer Research Education Grants Program:
- Notices of Intent to Publish Funding Opportunities Announcement for Nutrition for Precision Health, powered by the All of Us Research Program:
- Artificial Intelligence for Multimodal Data Modeling and Bioinformatics Center (U54, Clinical Trial Not Allowed)
- Metabolomics and Clinical Assays Center (U24)
- Microbiome and Metagenomics Center (U24, Clinical Trial Not Allowed)
- Dietary Assessment Center (U24, Clinical Trial Optional)
- Clinical Centers (UG1, Clinical Trial Required)
- Research Coordinating Center (U24, Clinical Trial Not Allowed)
- Research Supplements to Promote Diversity in Health-Related Research (Admin Supp, Clinical Trial Not Allowed)
Grants Policy Notices
- Extended Guidance for Applicants Preparing Applications During the COVID-19 Pandemic (NOT-OD-21-026)
- Final NIH Policy for Data Management and Sharing (NOT-OD-21-013)
- Supplemental Information to the NIH Policy for Data Management and Sharing:
- NIH Implementation of the Revised Federal-wide Research Terms and Conditions (NOT-OD-21-029)
Request for Information (RFI)
- Request for Information (RFI): Inviting Comments and Suggestions on the NIH-Wide Strategic Plan for COVID-19 Research (NOT-OD-21-018)
NIH Blog Posts
- NCI Bottom Line Blog - NCI’s New Fiscal Year Brings Old Fiscal Challenges
- NIH Director’s Blog - Genome Data from Africa Reveal Millions of New Variants
- Cancer Currents Blog - Why Is Colorectal Cancer Rising Rapidly among Young Adults?